Literature DB >> 30941793

Fine-tuning of the automated [18 F]PSMA-1007 radiosynthesis.

Ofer Shamni1, Bruno Nebeling2, Hilbert Grievink1, Eyal Mishani1.   

Abstract

Radiolabeled prostate-specific membrane antigen (PSMA) targeting PET-tracers have become desirable radiopharmaceuticals for the imaging of prostate cancer (PC). Recently, the PET radiotracer [18 F]PSMA-1007 was introduced as an alternative to [68 Ga]Ga-PSMA-11, for staging and diagnosing biochemically recurrent PC. We incorporated a one-step procedure for [18 F]PSMA-1007 radiosynthesis, using both Synthra RNplus and GE TRACERlab FxFN automated modules, in accordance with the recently described radiolabeling procedure. Although the adapted [18 F]PSMA-1007 synthesis resulted in repeatable radiochemical yields (55 ± 5%, NDC), suboptimal radiochemical purities of 87 ± 8% were obtained using both modules. As described here, modifications made to the radiolabeling and the solid-phase extraction purification steps reduced synthesis time to 32 minutes and improved radiochemical purity to 96.10%, using both modules, without shearing the radiochemical yield.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  PET; PSMA; [18F]PSMA-1007; fluorine-18; prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 30941793     DOI: 10.1002/jlcr.3732

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  1 in total

1.  False Positive Findings of [18F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels.

Authors:  Marina Orevi; Simona Ben-Haim; Galith Abourbeh; Alexandre Chicheportiche; Eyal Mishani; Vladimir Yutkin; Ofer N Gofrit
Journal:  Front Surg       Date:  2022-06-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.